MISTY LANCE: Open Payments
NPI 1750838983 · AMARILLO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,518 in 132 payments from 17 companies in 2025. Trend: 2023 $1,801 · 2024 $2,282 · 2025 $2,518
Food & beverage: $2,434Education: $84
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 21 | $388 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $347 |
| ABBVIE INC. | 19 | $233 |
| Gilead Sciences, Inc. | 10 | $220 |
| GENZYME CORPORATION | 8 | $203 |
| Madrigal Pharmaceuticals | 10 | $195 |
| QOL Medical, LLC | 7 | $172 |
| Phathom Pharmaceuticals, Inc. | 12 | $166 |
| Amgen Inc. | 1 | $117 |
| Regeneron Healthcare Solutions, Inc. | 6 | $115 |
Products named: TREMFYA, ENTYVIO, DUPIXENT, REZDIFFRA, Sucraid, VOQUEZNA, UPLIZNA, IBSRELA.
Industry payments across TX — which companies pay providers there.
